NASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis $7.70 +0.44 (+6.06%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$7.64 -0.06 (-0.78%) As of 05/2/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeoGenomics Stock (NASDAQ:NEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeoGenomics alerts:Sign Up Key Stats Today's Range$7.22▼$7.8650-Day Range$6.39▼$10.8852-Week Range$6.08▼$19.12Volume3.64 million shsAverage Volume1.08 million shsMarket Capitalization$990.66 millionP/E RatioN/ADividend YieldN/APrice Target$14.50Consensus RatingModerate Buy Company OverviewNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More… NeoGenomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreNEO MarketRank™: NeoGenomics scored higher than 65% of companies evaluated by MarketBeat, and ranked 327th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageNeoGenomics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NeoGenomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -12.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -12.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.93% of the float of NeoGenomics has been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently increased by 2.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.93% of the float of NeoGenomics has been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently increased by 2.89%, indicating that investor sentiment is decreasing. News and Social Media2.8 / 5News Sentiment0.02 News SentimentNeoGenomics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for NeoGenomics this week, compared to 5 articles on an average week.Search Interest13 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.MarketBeat Follows2 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeoGenomics' insider trading history. Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address NEO Stock News HeadlinesNeoGenomics, Inc (NEO) Q1 2025 Earnings Call TranscriptMay 1 at 8:21 AM | seekingalpha.comNeoGenomics Pays Off 1.25% Convertible Senior NotesMay 1 at 8:21 AM | finance.yahoo.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 3, 2025 | Golden Portfolio (Ad)NeoGenomics (NASDAQ:NEO) Shares Gap Down on Analyst DowngradeMay 1 at 1:17 AM | americanbankingnews.comNeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)April 30 at 9:00 AM | seekingalpha.comFort Myers-based NeoGenomics sees a strong start to 2025, with more growth expected this yearApril 30 at 5:43 AM | msn.comNeoGenomics (NASDAQ:NEO) Reaches New 1-Year Low on Analyst DowngradeApril 30 at 1:29 AM | americanbankingnews.comWhy NeoGenomics (NEO) Stock Is NosedivingApril 29, 2025 | finance.yahoo.comSee More Headlines NEO Stock Analysis - Frequently Asked Questions How have NEO shares performed this year? NeoGenomics' stock was trading at $16.48 at the beginning of 2025. Since then, NEO stock has decreased by 53.3% and is now trading at $7.70. View the best growth stocks for 2025 here. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, April, 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.06. The company's revenue for the quarter was up 7.6% compared to the same quarter last year. Read the conference call transcript. Does NeoGenomics have any subsidiaries? The following companies are subsidiaries of NeoGenomics: Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and others. Who are NeoGenomics' major shareholders? NeoGenomics' top institutional shareholders include Brown Advisory Inc. (3.01%), Segall Bryant & Hamill LLC (1.83%), Emerald Advisers LLC (0.67%) and Bank of New York Mellon Corp (0.62%). View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AUO (AUOTY). Company Calendar Last Earnings4/29/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Testing laboratories Sub-IndustryBusiness Services Current SymbolNASDAQ:NEO CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$14.50 High Stock Price Target$22.00 Low Stock Price Target$8.50 Potential Upside/Downside+88.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,970,000.00 Net Margins-11.92% Pretax Margin-12.21% Return on Equity-2.10% Return on Assets-1.17% Debt Debt-to-Equity Ratio0.38 Current Ratio1.98 Quick Ratio1.91 Sales & Book Value Annual Sales$672.36 million Price / Sales1.47 Cash Flow$0.28 per share Price / Cash Flow27.03 Book Value$7.02 per share Price / Book1.10Miscellaneous Outstanding Shares128,657,000Free Float126,791,000Market Cap$990.66 million OptionableOptionable Beta1.41 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NEO) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.